With a median follow-up of six years, 04 events (relapse) were observed in the CHOP+rituximab group and 09 in the CHOP group (in 20% and 45% of patients, respectively).
Theo dõi trung bình 06 năm, nhóm CHOP + Rituximab có 04 trường hợp (20%) tái phát, thấp hơn nhóm CHOP đơn thuần (45%).